<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584619</url>
  </required_header>
  <id_info>
    <org_study_id>31PMCF-DrG</org_study_id>
    <nct_id>NCT04584619</nct_id>
  </id_info>
  <brief_title>Idys™ TLIF 3DTi Post Market Clinical Follow-up</brief_title>
  <official_title>Clariance Idys™ TLIF 3DTi Device Prospective Post Market Clinical Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clariance</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clariance</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational post-marketing study is to provide additional information on&#xD;
      the safety and effectiveness of Idys™ TLIF 3DTi at up to 24 months post transforaminal lumbar&#xD;
      fusion in usual surgical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is to evaluate the effectiveness of the Idys™ TLIF (Transforaminal&#xD;
      Lumbar Interbody Fusion) 3DTi (Porous Titanium additive manufacturing) by measuring the&#xD;
      evolution of the rate of fusion during the postoperative period.&#xD;
&#xD;
      The secondary endpoints are to analyze the safety and the patient's benefit of the Idys™ TLIF&#xD;
      3DTi by evaluating several point of view:&#xD;
&#xD;
        -  The adverse events related to the surgery;&#xD;
&#xD;
        -  The functional improvement between preoperative state and the different follow-up time&#xD;
           points using the Oswestry Disability Index (ODI);&#xD;
&#xD;
        -  The improvement of back pain between preoperative state and the different follow-up time&#xD;
           points using the Visual Analog Scale (VAS) (legs and back);&#xD;
&#xD;
        -  The evolution of several radiologic lumbar parameters to assess the correction and its&#xD;
           stability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the Fusion rate</measure>
    <time_frame>6 months, 12 months, 24 months postoperatively</time_frame>
    <description>Evolution of the radiological assessment of bony fusion at 3 different time point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 24 months postoperatively</time_frame>
    <description>To quantify and describe adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the Patient Disability</measure>
    <time_frame>Preoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively</time_frame>
    <description>Assessment, at different time points, of the disability using Oswestry Disability Index score (range 0 to 100 with zero corresponding to no disability and 100 corresponding to the maximum disability possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the Patient Pain</measure>
    <time_frame>Preoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively</time_frame>
    <description>Assessment, at different time points, of the pain using Visual Analogue Scale (range 0 to 10 with higher scores meaning a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic Outcomes - Evolution of the lordosis angles (degree)</measure>
    <time_frame>Preoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively</time_frame>
    <description>Measurements, on x-rays at different time points, of the lordosis angle at pathological / implanted level and of the global lordosis angle between L1/S1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic Outcomes - Evolution of the Intervertebral Height (mm)</measure>
    <time_frame>Preoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively</time_frame>
    <description>Measurements, on x-rays at different time points, of the anterior and the posterior inter-vertebral height.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic Outcomes - Stability of the Idys TLIF 3DTi Device</measure>
    <time_frame>6 weeks, 6 months, 12 months and 24 months postoperatively</time_frame>
    <description>Measurement ,on x-rays at different time points, of the anterior position of the Idys TLIF 3DTi device</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Grade 1 Spondylolisthesis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spine fusion surgery with Clariance Idys TLIF 3DTi</intervention_name>
    <description>Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who need fusion of spinal lumbar segments&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English Speaking patients&#xD;
&#xD;
          -  Patient with skeletal maturity&#xD;
&#xD;
          -  Patient with&#xD;
&#xD;
               -  degenerative disc disease at one or two levels from L2 to S1 and/or&#xD;
&#xD;
               -  grade 1 spondylolisthesis&#xD;
&#xD;
          -  Surgical treatment with Idys TLIF 3DTi interbody fusion device used in conjunction&#xD;
             with a posterior fixation system (pedicle screws and rod).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Off-label indications.&#xD;
&#xD;
          -  Any medical or surgical condition which would preclude the potential benefit of spinal&#xD;
             implant surgery.&#xD;
&#xD;
          -  Any patient having a prior fusion at the level to be treated.&#xD;
&#xD;
          -  Any patient being vulnerable&#xD;
&#xD;
          -  Non-English speakers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mukund Gundanna, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brazos Spine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wassila Benkhedda</last_name>
    <phone>+33321161215</phone>
    <email>clinical-research@clariance-spine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brazos Spine</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Hagler</last_name>
      <phone>979-693-1815</phone>
      <email>office@brazosspine.com</email>
    </contact>
    <investigator>
      <last_name>Mukund Gundanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spine</keyword>
  <keyword>Interbody fusion device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

